CONTEXT THERAPEUT.DL-001
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more
Market Cap & Net Worth: CONTEXT THERAPEUT.DL-001 (6K9)
CONTEXT THERAPEUT.DL-001 (F:6K9) has a market capitalization of $226.35 Million (€220.51 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #18335 globally and #1924 in its home market, demonstrating a -0.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CONTEXT THERAPEUT.DL-001's stock price €2.40 by its total outstanding shares 91879177 (91.88 Million).
CONTEXT THERAPEUT.DL-001 Market Cap History: 2021 to 2026
CONTEXT THERAPEUT.DL-001's market capitalization history from 2021 to 2026. Data shows change from $222.10 Million to $226.35 Million (-17.91% CAGR).
CONTEXT THERAPEUT.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CONTEXT THERAPEUT.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6K9 by Market Capitalization
Companies near CONTEXT THERAPEUT.DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to CONTEXT THERAPEUT.DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CONTEXT THERAPEUT.DL-001 Historical Marketcap From 2021 to 2026
Between 2021 and today, CONTEXT THERAPEUT.DL-001's market cap moved from $222.10 Million to $ 226.35 Million, with a yearly change of -17.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €226.35 Million | +142.42% |
| 2025 | €93.37 Million | -1.98% |
| 2024 | €95.25 Million | +1.00% |
| 2023 | €94.31 Million | +73.07% |
| 2022 | €54.49 Million | -75.46% |
| 2021 | €222.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of CONTEXT THERAPEUT.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $226.35 Million USD |
| MoneyControl | $226.35 Million USD |
| MarketWatch | $226.35 Million USD |
| marketcap.company | $226.35 Million USD |
| Reuters | $226.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.